Latest news with #AID
New York Times
2 days ago
- Politics
- New York Times
Bush, Obama and Bono Commend USAID Staff Members on Their Last Day
As most staff members at the U.S. Agency for International Development marked their final day with the agency, they got thanks from two presidents and a rock star. The Trump administration has eliminated the bulk of U.S. foreign assistance programming, saying that such work fails to advance the American national interest. Top officials, including Secretary of State Marco Rubio and the former Trump adviser Elon Musk, worked to dismantle U.S.A.I.D. arguing that its staff was insubordinate. But in recorded messages shared with employees during a videoconference on Monday, former presidents painted a very different picture of the agency and its place in American foreign policy. 'You've shown the great strength of America through your work, and that is our good heart,' former President George W. Bush told staff in a video message. The video, a copy of which was viewed by The New York Times, was reported earlier by The Associated Press. Mr. Bush cited the President's Emergency Plan for AIDS Relief, which he initiated, and which has been estimated to have saved 25 million lives. That program's future, like much of U.S. foreign aid, is unclear. 'Is it in our interest that 25 million people who would have died now live? I think it is,' Mr. Bush said. 'On behalf of a grateful nation, thank you for your hard work, and God bless you.' Former President Barack Obama, in a separate message, said the decision to dismantle U.S.A.I.D. would 'go down as a colossal mistake.' 'Ending your presence and your programs out in the world hurts the most vulnerable, and it hurts the United States,' Mr. Obama said, citing the agency's efforts to prevent disease, fight drought and build schools. 'To many people around the world, U.S.A.I.D. is the United States,' Mr. Obama added. He encouraged the agency's staff to take pride in their work, even as they looked for new jobs. Bono, the U2 frontman and longtime advocate for developing countries, offered a lyrical send-off in a video of his own. 'They called you crooks — when you were the best of us, there for the rest of us,' he said. 'And don't think any less of us, when politics makes a mess of us.' 'It's not left-wing rhetoric to feed the hungry, heal the sick,' Bono added. 'If this isn't murder, I don't know what is.'
Yahoo
23-06-2025
- Health
- Yahoo
Tandem's t:slim X2 pump now works with Abbott's FreeStyle CGM sensor
Tandem Diabetes Care has announced its Tandem t:slim X2 insulin pump is now compatible with Abbott's FreeStyle Libre 3 Plus continuous glucose monitoring (CGM) sensor. The early access programme for this integration has already started in the US, with plans to scale the availability in the second half of this year. With its extended 15-day wear duration, the FreeStyle Libre 3 Plus sensor provides minute-by-minute glucose readings that are directly transmitted to the pump. This allows the data to be viewed on the t:slim mobile app, offering users access to their present glucose trends. Powered by the Control-IQ+ technology, the t:slim X2 insulin pump claims to be the newest generation of hybrid closed-loop algorithm of Tandem, which will adjust insulin delivery every five minutes based on predicted glucose levels. The system's AutoBolus feature is designed to calculate and deliver correction boluses, which help manage missed meal boluses. This technology has ease of use and personalisation, and with this new integration, it extends its benefits to a broader range of individuals with diabetes. Notably, the insulin pump allows users to update features remotely using a personal computer, ensuring that the pump remains equipped with the latest technology throughout its warranty time. Tandem Diabetes Care chief medical officer Dr Jordan Pinsker said: 'Diabetes management is not one-size-fits-all, and it is critical for people living with diabetes to be able to personalise their AID systems to fit their unique healthcare and lifestyle needs. 'The American Diabetes Association recommends AID systems as the preferred insulin delivery method in people with type 1 and other types of insulin-deficient diabetes, and this integration with Abbott's latest generation sensor allows even more CGM users to access the life-changing benefits of our Control-IQ+ technology.' In February 2025, the US Food and Drug Administration (FDA) cleared Tandem Diabetes Care's Control-IQ+ technology, making it available for use by individuals aged 18 and above with type 2 diabetes. "Tandem's t:slim X2 pump now works with Abbott's FreeStyle CGM sensor" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Yahoo
20-06-2025
- Health
- Yahoo
Tandem Diabetes Care Announces t:slim X2™ Insulin Pump Compatibility with Abbott's FreeStyle Libre® 3 Plus Sensor in the United States
Tandem continues to build its technology ecosystem to expand choice and personalization for people living with diabetes SAN DIEGO, June 20, 2025--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company today announced the Tandem t:slim X2™ insulin pump with Control-IQ+ automated insulin delivery (AID) technology now works with Abbott's FreeStyle Libre® 3 Plus continuous glucose monitoring (CGM) sensor. The Company has initiated an early access program in the United States (U.S.), and intends to scale availability in the second half of 2025. "Diabetes management is not one-size-fits-all and it is critical for people living with diabetes to be able to personalize their AID systems to fit their unique healthcare and lifestyle needs," said Dr. Jordan Pinsker, chief medical officer of Tandem Diabetes Care. "The American Diabetes Association recommends AID systems as the preferred insulin delivery method in people with type 1 and other types of insulin-deficient diabetes, and this integration with Abbott's latest generation sensor allows even more CGM users to access the life-changing benefits of our Control-IQ+ technology." The FreeStyle Libre 3 Plus sensor has an extended 15-day wear time, transmitting automatic glucose readings every minute directly to the pump. This data is also available to view on the Tandem t:slim mobile app, providing users with multiple, convenient ways to access their current glucose trend. The t:slim X2 insulin pump is powered by Control-IQ+ technology, the latest generation of Tandem's advanced hybrid closed-loop algorithm, which adjusts insulin every 5 minutes based on predicted glucose values. It's the only system with the unique AutoBolus™ feature that calculates and delivers a correction bolus to help with missed meal boluses.* Control-IQ+ is easy to start, use, and personalize, and this latest integration works with the FreeStyle Libre 3 Plus sensor and extends its benefits to even more people with diabetes. "This is an exciting first step in our strategy to connect Tandem's portfolio of insulin pumps to Abbott's FreeStyle Libre 3 Plus sensors worldwide," said John Sheridan, president and chief executive officer of Tandem Diabetes Care. "We look forward to expanding access to our t:slim X2 users outside of the U.S. beginning later this year." When available, Tandem will email eligible users in the U.S. with more information.† About Tandem Diabetes CareTandem Diabetes Care, a global insulin delivery and diabetes technology company, manufactures and sells advanced automated insulin delivery systems that reduce the burden of diabetes management, while creating new possibilities for patients, their loved ones, and healthcare providers. The Company's pump portfolio features the Tandem Mobi system and the t:slim X2 insulin pump, both of which feature Control-IQ+ advanced hybrid closed-loop technology. Tandem Diabetes Care is based in San Diego, California. For more information, visit Follow Tandem Diabetes Care on X @tandemdiabetes; use #tslimX2 #TandemMobi and # Tandem Diabetes Care on Facebook at Tandem Diabetes Care on LinkedIn at Forward Looking StatementsThis press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements relate to, among other things, our ability to provide the software update for current t:slim X2 pump users and the t:slim X2 pumps pre-loaded with Freestyle Libre 3 Plus sensor integration software. These statements are subject to numerous risks and uncertainties, including our ability to sustain commercial scale manufacturing of the t:slim X2 pumps pre-loaded with Freestyle Libre 3 Plus sensor integration software, our ability to operate and maintain a system to facilitate online training for existing t:slim X2 pump customers upgrading their existing devices, and the risk that we may encounter other challenges that may delay the availability of the software update for current t:slim X2 pump users or the t:slim X2 pumps pre-loaded with Freestyle Libre 3 Plus sensor integration software. These and other risks are identified and described in greater detail under the "Risk Factors" heading of our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and other documents filed with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Actual results could differ materially from those anticipated or projected in the forward-looking statements. Tandem undertakes no obligation to update or review any forward-looking statement in this press release because of new information, future events, or other factors. Important Safety Information – FreeStyle Libre SystemsProduct for prescription only; for Important Safety Information, please visit Important Safety Information – Tandem Diabetes CareRX ONLY. The t:slim X2 pump with interoperable technology (the pump) and Control-IQ+ technology (Control-IQ+) are intended for single patient use. The pump and Control-IQ+ are indicated for use with NovoLog or Humalog U-100 insulin. t:slim X2 insulin pump: The pump is intended for the subcutaneous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in persons requiring insulin. The pump is able to reliably and securely communicate with compatible, digitally connected devices, including automated insulin dosing software, to receive, execute, and confirm commands from these devices. The pump is indicated for use in persons 2 years of age and greater. Control-IQ+ technology: Control-IQ+ technology is intended for use with compatible integrated continuous glucose monitors (iCGM, sold separately) and alternate controller enabled (ACE) pumps to automatically increase, decrease, and suspend delivery of basal insulin based on iCGM readings and predicted glucose values. It can also deliver correction boluses when the glucose value is predicted to exceed a predefined threshold. Control-IQ+ technology is intended for the management of Type 1 diabetes mellitus in persons 2 years of age and greater and of Type 2 diabetes mellitus in persons 18 years of age and greater. WARNING: Control-IQ+ should not be used in anyone under the age of 2 years old with Type 1 diabetes or under the age of 18 years old with Type 2 diabetes. It should also not be used in patients who require less than a total daily insulin dose of 5 units of insulin per day or who weigh less than 20 pounds (9 kilograms), as those are the required minimum values needed for Control-IQ+ to operate safely. Users of the pump and Control-IQ+ must: use the insulin pump, iCGM, and all other system components in accordance with their respective instructions for use. Failure to follow these instructions for use could result in an over delivery or under delivery of insulin. This can cause hypoglycemia (low BG) or hyperglycemia (high BG) events. Visit for additional important safety information. © 2025 Tandem Diabetes Care, Inc. All rights reserved. Tandem Diabetes Care, the Tandem logo, Control-IQ+, t:slim X2, t:slim, and Tandem Mobi are either registered trademarks or trademarks of Tandem Diabetes Care, Inc. in the United States and/or other countries. The sensor housing, FreeStyle, Libre, and related brand marks are marks of Abbott and used with permission. All other third-party marks are the property of their respective owners. * If glucose values are predicted to be above 180 mg/dL (or 10.0 mmol/L), Control-IQ technology calculates a correction bolus using the Personal Profile settings and a target of 110 mg/dL (or 6.1 mmol/L) and delivers 60% of that value. † Future updates for all or some Tandem products may not be developed and may not be offered everywhere and would be subject to applicable regulatory approvals. Software updates are only available to customers who are in warranty at the time they update their pump. Additional training may be required to access certain software updates. Charges may apply. Tandem may discontinue select software and features over time at its discretion. View source version on Contacts Media Contact: 858-366-6900media@ Investor Contact: 858-366-6900IR@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Time Business News
18-06-2025
- Business
- Time Business News
How AID Integrates Smart Contracts and DeFi Architecture Seamlessly
The Decentralized Finance (DeFi) landscape continues to evolve, with platforms like AID pushing the boundaries of innovation by offering secure, autonomous, and user-friendly blockchain solutions. In the world of DEFI, trustless systems and automated transactions are core principles—and AID exemplifies this by integrating smart contracts with scalable DeFi architecture. AID is not just another participant in the space; it is a builder, a visionary, and a catalyst for the next phase of decentralized finance. DeFi refers to an ecosystem of financial applications built on blockchain technologies that operate without centralized intermediaries. At the heart of this system are smart contracts—self-executing programs that enforce the terms of a contract when predefined conditions are met. These contracts form the backbone of AID's infrastructure. By embedding business logic directly into the blockchain, smart contracts eliminate the need for third-party oversight, reducing costs and increasing transaction speed. AID's DEFI architecture is designed around modularity, security, and scalability. This means the system is made up of independent, yet interoperable components that work together to deliver seamless financial services. AID deploys Ethereum Virtual Machine (EVM)-compatible smart contracts, which enable it to tap into a vast ecosystem of decentralized applications (dApps) and liquidity pools. Additionally, Layer-2 scaling solutions are used to ensure fast and low-cost transactions, a vital factor for mainstream DEFI adoption. AID ensures its smart contracts are deeply integrated into all its financial operations. The process begins with meticulous planning and design. Each contract is designed to perform a specific financial task—be it lending, borrowing, staking, or yield farming. Once the logic is finalized, contracts are developed using Solidity and rigorously audited to prevent exploits. After deployment, they interact directly with users through AID's user interface, executing complex transactions with a single click. These smart contracts can also communicate with oracles to access real-world data, such as price feeds or interest rates. Security remains a top priority in any DEFI platform, and AID takes a proactive approach. All smart contracts undergo both manual and automated audits by reputable blockchain security firms. Additionally, bug bounty programs are in place to incentivize ethical hackers to identify vulnerabilities. AID's architecture also includes built-in emergency features such as circuit breakers and upgradeable contracts, ensuring that the system can adapt to unforeseen threats without compromising user funds. One of the challenges facing DEFI adoption is the steep learning curve. AID addresses this by abstracting complex blockchain interactions behind a user-friendly interface. Instead of requiring users to understand gas fees or wallet mechanics, AID offers intuitive dashboards, clear instructions, and real-time analytics. Features like single-click staking, auto-compounding, and portfolio tracking empower users to engage with DEFI confidently and efficiently. All actions are transparently logged on-chain, promoting accountability and trust. In today's fragmented blockchain landscape, cross-chain functionality is a significant advantage. AID has built bridges with other blockchains such as Binance Smart Chain, Polygon, and Avalanche. This allows users to move assets freely between chains without relying on centralized exchanges. The smart contracts are written to be cross-chain compatible, ensuring the same high level of performance and security no matter the underlying blockchain. True to DEFI principles, AID incorporates decentralized governance into its smart contract framework. Token holders have voting rights on key protocol decisions—from interest rate changes to system upgrades. This governance mechanism is encoded in smart contracts, allowing proposals to be automatically enacted once consensus is reached. By decentralizing decision-making, AID ensures that its future development aligns with the community's interests. AID's DeFi ecosystem powers a range of real-world use cases. Its lending platform allows users to collateralize crypto assets and borrow stablecoins. Its staking module supports yield generation on various tokens. Additionally, AID facilitates decentralized insurance, liquidity mining, and even NFT-based finance. These services all operate through seamlessly integrated smart contracts, demonstrating the versatility of AID's DEFI architecture. Many DEFI platforms struggle with fragmented architecture and siloed smart contracts. AID stands out by designing its system holistically. Each smart contract is part of a broader framework, ensuring interoperability and minimizing friction. Whether a user is swapping tokens, providing liquidity, or voting on a governance proposal, the experience is unified and streamlined. This tight integration not only improves performance but also builds user trust and drives adoption. Despite its innovations, AID is not immune to the broader challenges of the DEFI space. Regulatory uncertainty, smart contract exploits, and scalability issues continue to pose risks. However, AID's development team—backed by years of experience in blockchain and Web3 product design—is actively working on solutions. Future plans include zk-rollups for increased privacy, AI-driven analytics, and partnerships with traditional financial institutions to expand DEFI's reach. AID exemplifies what it means to integrate smart contracts and DEFI architecture seamlessly. By focusing on modular design, security, usability, and governance, AID is helping shape a future where financial services are open, fair, and programmable. As the DEFI ecosystem continues to mature, platforms like AID will play a crucial role in delivering real value to users worldwide—bridging the gap between innovation and accessibility. TIME BUSINESS NEWS
Yahoo
18-06-2025
- Business
- Yahoo
ELISpot and Fluorospot Assay Market Set to Reach USD 528.30 Million by 2032, Driven by Immuno-Oncology Research and Diagnostic Innovation
SNS Insider Unveils Strategic Insights into the U.S. ELISpot and Fluorospot Assay Market's Rapid Growth—Valued at USD 79.68 Million in 2023—While the U.S. Commands Over 40% of the Global Share Amid Diagnostic Advancements in Immunology. Austin, June 18, 2025 (GLOBE NEWSWIRE) -- ELISpot and Fluorospot Assay Market Size & Growth Analysis: According to SNS Insider, the global ELISpot and Fluorospot Assay Market was valued at USD 290.92 million in 2023 and is projected to reach USD 528.30 million by 2032, growing at a CAGR of 6.85% during the forecast period of 2024–2032. The U.S. market alone was valued at USD 79.68 million in 2023, forecasted to climb to USD 138.33 million by 2032, with a CAGR of 6.32%.Get a Sample Report of ELISpot and Fluorospot Assay Market@ The growth trajectory is largely fueled by increasing applications in infectious disease diagnostics, cancer immunotherapy, and autoimmune disease research. As demand for highly sensitive immune response assays grows, these platforms are rapidly being adopted by hospitals, biotech firms, and academic labs. Market Overview The ELISpot and Fluorospot assays are gaining traction across immunological research and clinical diagnostics due to their precision in detecting immune responses. Widely utilized in vaccine development, autoimmune disease studies, and cancer immunotherapy, these assays are supported by the increasing demand for high-sensitivity diagnostics. The U.S. remains a key contributor to market growth, benefiting from strong research funding, a highly developed healthcare infrastructure, and the presence of major industry players. Globally, market expansion is further driven by the rising incidence of chronic and infectious diseases and the growing adoption of personalized medicine. Technological advancements in assay analyzers and kits are expected to fuel additional market momentum throughout the forecast period. Major Players Analysis Listed in this Report are: Becton, Dickinson, and Company (BD ELISPOT Assay System, BD FluoroSpot Assay Kit) U-CyTech biosciences (Human IFN-γ ELISPOT Kit, Monkey IL-4 FluoroSpot Kit) Cellular Technologies Limited (CTL) (ImmunoSpot Human IFN-γ ELISPOT Kit, ImmunoSpot Human IL-2/IL-4 FluoroSpot Kit) Mabtech AB (Human IFN-γ ELISpotPRO Kit, Human IL-2/IL-4 FluoroSpot Kit) Abcam (Human IFN-γ ELISPOT Kit, Human IL-17A/IL-22 FluoroSpot Kit) Oxford Immunotec ( Test, Test) Bio-Techne Corporation (Human IFN-γ ELISpot Kit, Human IL-10/IL-12 FluoroSpot Kit) Autoimmun Diagnostika GmbH (AID) (AID iSpot ELISPOT Plate Reader, AID iSpot Spectrum FluoroSpot Reader) Lophius Biosciences GmbH (T-Track ELISPOT Kit, T-Track CMV FluoroSpot Kit) Bio-Connect B.V. (Human TNF-α ELISPOT Kit, Human IL-5/IL-13 FluoroSpot Kit) Thermo Fisher Scientific (Mabtech Human IFN-γ ELISpot Kit, Mabtech Human IL-2/IL-4 FluoroSpot Kit) PerkinElmer Inc. (ATPlite Luminescence Assay System, LANCE Ultra TR-FRET Assay) R&D Systems (Human IFN-γ ELISPOT Kit, Human IL-17/IL-22 FluoroSpot Kit) Enzo Life Sciences (Human IFN-γ ELISPOT Kit, Human IL-4/IL-5 FluoroSpot Kit) MilliporeSigma (Merck KGaA) (ELISpot Plate Reader System, FluoroSpot Multi-Analyte Assay Kit) ImmunoDiagnostics Limited (Human IFN-γ ELISPOT Kit, Human IL-21/IL-22 FluoroSpot Kit) ALPCO (Human IFN-γ ELISPOT Kit, Human IL-10/IL-12 FluoroSpot Kit) RayBiotech Life, Inc. (Human IFN-γ ELISPOT Kit, Human IL-6/IL-8 FluoroSpot Kit) Cell Sciences (Human IFN-γ ELISPOT Kit, Human IL-2/IL-5 FluoroSpot Kit) ZellBio GmbH (Human IFN-γ ELISPOT Kit, Human IL-4/IL-10 FluoroSpot Kit) ELISpot and Fluorospot Assay Market Report Scope Report Attributes Details Market Size in 2023 USD 290.92 million Market Size by 2032 USD 528.30 million CAGR (2024–2032) 6.85% U.S. Market 2023 USD 79.68 million U.S. Forecast by 2032 USD 138.33 million Base Year 2023 Forecast Period 2024–2032 Key Regional Coverage North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, Poland, Turkey, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America) Segment Analysis By Product The assay kits segment captured the highest market share of 48.56% in 2023. This is due to the extensive use of assay kits in research and diagnostic applications. The need for high-sensitivity detection in immunological studies also contributes to the growth of this segment. The segment of analyzers will be growing at the highest rate. The high demand for automated and high-throughput analyzers in research and laboratory settings is driving the growth of this segment. These analyzers improve accuracy and efficiency, leading to increasing demand in the market. By Application The diagnostic applications market held 65.41% of the market share in 2023. The growing incidence of infectious diseases, autoimmune diseases, and cancer has driven the demand for ELISpot and Fluorospot assays in clinical diagnostics. These assays provide accurate and early detection, leading to their popularity in diagnostic laboratories and healthcare facilities. The research applications segment is expected to witness the most rapid growth. The growing emphasis on immunological research, vaccine discovery, and T-cell monitoring in cancer and infectious disease research is propelling the growth of this segment. Growing funding and advances in technology are also driving its rapid growth. By End Use The hospitals and clinical laboratories segment accounted for the largest share of 47.25% in 2023. The rising need for sophisticated diagnostic equipment in healthcare facilities, as well as the rising number of hospital-based research studies, has supported the application of ELISpot and Fluorospot assays in hospitals and clinical labs. The biopharmaceutical and research institutes segment is expected to grow at the fastest rate. The growing investment in drug discovery and immunological research by academic institutions and pharmaceutical companies is fueling the demand for these assays in research settings. For A Detailed Briefing Session with Our Team of Analysts, Connect with Us Now@ ELISpot and Fluorospot Assay Market Segmentation By Product Assay Kits Analyzers Ancillary Products By Application Research Applications Diagnostics Applications By End Use Hospital and Clinical Labs Academic and Research Institutes Biopharmaceutical Company Regional Insights North America dominated the worldwide market in 2023 with a share of 36.25%, driven by its well-developed healthcare infrastructure, robust research culture, and high prevalence of adoption of next-generation diagnostic technologies. The United States is particularly prominent because of high government and private investment in immunology and infectious disease research. The Asia-Pacific market is expected to have the highest growth rate until 2032. The major drivers include the growth of healthcare infrastructure, higher R&D spending, and an increasing prevalence of infectious diseases. Recent Developments February 2025: BD announced the separation of its Biosciences and Diagnostic Solutions business to enhance strategic focus and growth, potentially impacting its immunoassay product offerings, including ELISpot and Fluorospot assays. April 2024: U-CyTech Biosciences was recognized as a leading company in the ELISpot and Fluorospot assay market, significantly contributing to immunological research and clinical diagnostics. February 2024: Cellular Technology Limited (CTL) was identified as a major player in the ELISpot and Fluorospot assay market, with substantial contributions to assay development and distribution. Statistical Insights and Trends Reporting The United States accounted for approximately 40% of the global market share in 2023, driven by extensive research funding and strong healthcare infrastructure. The total number of ELISpot and Fluorospot assay kits and analyzers deployed worldwide is expected to increase by 70% between 2024 and 2032. The spending on immunology-based diagnostics, including ELISpot and Fluorospot assays, increased by 9.5% in 2023, reflecting the growing focus on early disease detection. The use of ELISpot and Fluorospot assays in immuno-oncology research is expected to grow by 85% by 2032, driven by increasing interest in personalized medicine and T-cell monitoring. Buy a Single-User PDF of ELISpot and Fluorospot Assay Market Analysis & Outlook Report 2024-2032@ Table of Contents – Major Key Points 1. Introduction 2. Executive Summary 3. Research Methodology 4. Market Dynamics Impact Analysis 5. Statistical Insights and Trends Reporting 5.1 Incidence and Prevalence of Immune-related Diseases (2023) 5.2 Research and Clinical Adoption Trends, by Region (2023) 5.3 Assay Kit and Analyzer Volume, by Region (2020-2032) 5.4 Assay Kit and Analyzer Volume, by Region (2020-2032) 6. Competitive Landscape 7. ELISpot and Fluorospot Assay Market by Product 8. ELISpot and Fluorospot Assay Market by Application 9. ELISpot and Fluorospot Assay Market by End Use 10. Regional Analysis 11. Company Profiles 12. Use Cases and Best Practices 13. Conclusion About Us: SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world. CONTACT: Contact Us: Jagney Dave - Vice President of Client Engagement Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK) Email: info@
